share_log

Retail Investors Among Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop

Retail Investors Among Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop

以昭衍新药(中国)有限公司(SHSE:603127)为代表的散户是最大股东之一,在上周股价下跌9.5%后受到影响。
Simply Wall St ·  08/23 03:17

Key Insights

主要见解

  • Significant control over Joinn Laboratories(China)Co.Ltd by retail investors implies that the general public has more power to influence management and governance-related decisions
  • The top 13 shareholders own 50% of the company
  • 39% of Joinn Laboratories(China)Co.Ltd is held by insiders
  • 零售投资者对昭衍新药(中国)有限公司拥有重要的控制权,这意味着普通公众对管理和治理相关决策有更大的影响力。
  • 前13名股东占该公司50%的股份。
  • 昭衍新药(中国)有限公司39%的股份由内部人士持有。

A look at the shareholders of Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 42% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

看一下昭衍新药(中国)有限公司(SHSE:603127)的股东,我们可以了解哪个群体更具影响力。持有最大股份的是零售投资者,拥有42%的所有权。换句话说,该群体面临着最大的上行潜力(或下行风险)。

Following a 9.5% decrease in the stock price last week, retail investors suffered the most losses, but insiders who own 39% stock also took a hit.

上周股价下跌了9.5%,零售投资者遭受最大损失,但持有39%股份的内部人员也受到打击。

In the chart below, we zoom in on the different ownership groups of Joinn Laboratories(China)Co.Ltd.

在下面的图表中,我们将聚焦昭衍新药(中国)有限公司的不同所有权群体。

1724397431521
SHSE:603127 Ownership Breakdown August 23rd 2024
SHSE:603127所有权拆分2024年8月23日

What Does The Institutional Ownership Tell Us About Joinn Laboratories(China)Co.Ltd?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。

As you can see, institutional investors have a fair amount of stake in Joinn Laboratories(China)Co.Ltd. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Joinn Laboratories(China)Co.Ltd's historic earnings and revenue below, but keep in mind there's always more to the story.

正如您所见,机构投资者在昭衍新药(中国)有限公司中持有相当大比例的股份。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时也会做出糟糕的投资决策,就像每个人都有可能犯错一样。当多家机构持有某只股票时,总会存在它们在一个“拥挤交易”的风险。当这样的交易出错时,多方可能会争相快速卖出股票。这种风险在没有增长历史的公司中更高。您可以在下面看到昭衍新药(中国)有限公司的历史盈利和营业收入,但请记住故事还有更多内容。

1724397432964
SHSE:603127 Earnings and Revenue Growth August 23rd 2024
SHSE:603127在2024年8月23日的收入和营业收入增长

Hedge funds don't have many shares in Joinn Laboratories(China)Co.Ltd. Our data suggests that Yuxia Feng, who is also the company's Top Key Executive, holds the most number of shares at 22%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. Zhi Wen Zhou is the second largest shareholder owning 10% of common stock, and Zhong Ou Fund Management Co., Ltd holds about 3.2% of the company stock.

对冲基金在昭衍新药(中国)有限公司的持股不多。我们的数据表明,冯玉侠,也是公司的最高主要执行官,持有公司22%的股份。当内部人士持有公司的大量股票时,投资者会认为这是一个积极的迹象,因为这表明内部人士愿意将自己的财富绑定在公司的未来。 周之文是第二大股东,拥有10%的普通股,而中欧基金管理有限公司持有公司股票的大约3.2%。

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership.

通过查看股东登记表,我们可以看到前13大股东控制了50%的所有权,这意味着没有单个股东拥有多数股权。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

研究机构持股比例是衡量和筛选股票预期表现的好方法。同样可以通过研究分析师情绪来实现。由于相当多的分析师都关注着该股票,因此你可以很容易地研究预测的增长。

Insider Ownership Of Joinn Laboratories(China)Co.Ltd

昭衍新药(中国)有限公司的内部股权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同国家,内部人员的定义可能会略有不同,但董事会成员始终是内部人员。管理层最终向董事会负责。然而,如果管理人员是创始人或CEO,那么成为执行董事会成员也是很常见的。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。

Our information suggests that insiders maintain a significant holding in Joinn Laboratories(China)Co.,Ltd.. It has a market capitalization of just CN¥9.1b, and insiders have CN¥3.5b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我们的信息显示,内部人士在昭衍新药(中国)股份有限公司中持有大量股份。它的市值仅为91亿元人民币,内部人士有价值35亿元人民币的股份。这相当重要。大多数人会说,尤其是在这样一个规模的公司中,这显示了与股东的良好一致性。您可以点击这里查看内部人士是否有买卖。

General Public Ownership

一般大众所有权

The general public, who are usually individual investors, hold a 42% stake in Joinn Laboratories(China)Co.Ltd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

一般公众,通常是个人投资者,持有昭衍新药(中国)股份有限公司42%的股份。尽管这种所有权规模可能不足以左右政策决策对他们的青睐,但他们仍然可以对公司政策产生集体影响。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Joinn Laboratories(China)Co.Ltd is showing 1 warning sign in our investment analysis , you should know about...

虽然考虑到公司的不同股东群体是非常值得的,但还有其他更重要的因素需要考虑。请注意,昭衍新药(中国)有限公司在我们的投资分析中显示出了1个警告信号,您应该知道...

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发